Anti-Allergy Botanical Composition for Long-Term Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological treatments for allergic and inflammatory conditions, such as antihistamines and corticosteroids, have significant side effects that can be harmful to patients, particularly when used over prolonged periods.
Innovation Solution
A novel mixture comprising boswellia, blackcurrant, helichrysum, perilla, and quercetin, optionally with feverfew, apple, elderberry, or probiotic bacteria, which interferes with Th2-type allergic inflammation and autoimmune inflammation without causing chemical or hormonal side effects, and does not interfere with cytochrome P450 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antihistamines and corticosteroids are used to treat allergic and inflammatory conditions, then therapeutic effectiveness is improved, but side effects increase
Solution Approach 1:
The patent changes the chemical composition parameters by replacing conventional antihistamines and corticosteroids with a natural mixture containing boswellia, blackcurrant, helichrysum, perilla, and quercetin. This parameter change maintains therapeutic effectiveness while eliminating the harmful side effects associated with conventional medications, particularly when used over prolonged periods.
Solution Approach 2:
The patent employs a composite material approach by creating a multi-component natural mixture where boswellia, blackcurrant, helichrysum, perilla, and quercetin work synergistically. This composite formulation achieves the therapeutic effects of conventional medications without producing harmful side effects, resolving the contradiction between effectiveness and safety.
2Duration of action of stationary object
If conventional pharmacological treatments are used over prolonged periods, then therapeutic outcomes are maintained, but harmful side effects accumulate
Solution Approach 1:
The patent changes the temporal parameter by enabling prolonged treatment duration with the natural mixture without the accumulation of harmful side effects. The composition allows for long-term use in various patient categories, transforming the treatment duration parameter from a limited factor to an extended factor while maintaining safety.
3Object-generated harmful factors
If natural ingredients are used instead of conventional drugs, then side effects are minimized, but therapeutic effectiveness may be reduced
Solution Approach 1:
The patent resolves this contradiction by using a composite material consisting of five natural ingredients (boswellia, blackcurrant, helichrysum, perilla, and quercetin) that work synergistically. This composite formulation achieves therapeutic effectiveness comparable to conventional medications while maintaining the safety profile of natural ingredients, thus resolving the contradiction between natural composition and therapeutic reliability.
Solution Approach 2:
The patent merges multiple natural ingredients with complementary anti-inflammatory and antiallergic properties into a single formulation. By combining boswellia, blackcurrant, helichrysum, perilla, and quercetin, the patent creates a synergistic effect that matches or exceeds the therapeutic effectiveness of conventional drugs while eliminating their harmful side effects.
Data Source
AI summary
The present invention relates to a mixture comprising or, alternatively, consisting of boswellia, blackcurrant, helichrysum, perilla, quercetin and, optionally, at least one ingredient selected from the group comprising or, alternatively, consisting of a feverfew extract, apple extract, elderberry extract, one or more strains of probiotic bacteria and/or mixtures thereof, useful in the treatment of allergic and/or inflammatory conditions and symptoms, in particular allergic inflammation, on the one hand, and autoimmune and systemic inflammation, on the other. Furthermore, the invention also refers to pharmaceutical compositions and/or compositions for medical devices (Regulation (EU) 2017/745) and/or nutraceuticals and/or food which comprise such novel mixture and to their use in therapy, in the treatment of allergic and/or inflammatory states and symptoms, in particular allergic inflammation, on the one hand, and autoimmune and systemic inflammation, on the other.